OncoMatch/Clinical Trials/NCT06057402
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Is NCT06057402 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Elranatamab for multiple myeloma.
Treatment: Elranatamab — This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Prior therapy
Must have received: elranatamab (elranatamab) — Parent Study
Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).
Cannot have received:
Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCHealth Poudre Valley Hospital · Fort Collins, Colorado
- UCHealth Harmony · Fort Collins, Colorado
- UCHealth Greeley Hospital · Greeley, Colorado
- Longs Peak Hospital · Longmont, Colorado
- UCHealth Longs Peak Medical Center · Longmont, Colorado
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify